Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Alzheimer’s disease patients may benefit from new biomarkers

Key clinical point: New biomarkers representing Aβ- and tau-independent Alzheimer’s disease pathology could promote monitoring of patients during therapies targeting Aβ and tau proteins.

Major finding: Several biomarkers have emerged for use in Alzheimer’s disease including chromogranin-A in the neurodegeneration category, β2-microglobulin in the inflammation-related category, Apolipoprotein E in the lipid metabolism-related category, and clusterin in the protein clearance-related category.

Study details: The data come from a review of the clinical utility of new biomarkers for characterizing Alzheimer’s disease.

Disclosures: The study was supported by the Basic Science Research Program and the Original Technology Research Program for Brain Science of the National Research Foundation of Korea funded by the Korean government. The researchers had no financial conflicts to disclose.

Citation:

Park SA et al. Exp Mol Med. 2020 Apr 13. doi: 10.1038/s12276-020-0418-9.